Stock events for Tango Therapeutics, Inc. (TNGX)
Tango Therapeutics' stock has experienced significant activity. The stock price saw a substantial increase of 413.36% over the last six months. On October 23, 2025, the stock experienced volatility, dropping initially but rising in pre-market trading after financing and data announcements. The stock reached a new 52-week high of $10.00 on October 24, 2025. On August 5, 2025, Tango Therapeutics reported its Q2 2025 earnings, with revenue dropping 52% and missing analyst estimates. Analyst ratings and price targets have been updated by Guggenheim, Piper Sandler, and Weiss Ratings. On October 27, 2025, Tango Therapeutics was upgraded to a Zacks Rank #2 (Buy).
Demand Seasonality affecting Tango Therapeutics, Inc.’s stock price
There are seasonal patterns in Tango Therapeutics' stock performance rather than in the demand for its products or services. Seasonal signals for the stock were balanced for October, with a statistically strong window anticipated around November 13, 2025.
Overview of Tango Therapeutics, Inc.’s business
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering and developing precision cancer medicines, operating within the Health Technology sector and Biotechnology industry. They utilize the genetic principle of synthetic lethality to identify novel drug targets and develop therapies that selectively target cancer cells. Their pipeline includes TNG462 (Vopimetostat), a PRMT5 inhibitor in Phase 1/2 clinical trials; TNG456, a brain-penetrant PRMT5 inhibitor for glioblastoma; TNG260, a CoREST inhibitor; and TNG348, an allosteric USP1 inhibitor.
TNGX’s Geographic footprint
Tango Therapeutics, Inc. is headquartered in Boston, Massachusetts. Its operations are focused on research and development and clinical trials.
TNGX Corporate Image Assessment
No specific events negatively impacted Tango Therapeutics' brand reputation in the past year. Positive clinical data and successful financing rounds contribute positively to the company's reputation.
Ownership
Institutional investors and hedge funds hold approximately 78.99% of Tango Therapeutics' shares. Major institutional owners include TRV GP IV, LLC, TCG Crossover Management, LLC, EcoR1 Capital, LLC, Boxer Capital Management, LLC, Farallon Capital Management LLC, Woodline Partners LP, Adage Capital Partners GP, L.L.C., Nextech Invest, Ltd., BlackRock, Inc., Gilead Sciences Inc., Third Rock Ventures IV, L.P., T. Rowe Price Investment Management, Balyasny Asset Management L.P., and Nantahala Capital Management LLC.
Ask Our Expert AI Analyst
Price Chart
$8.01
